

**Table S1. The non-overlapping MA and MO GWA studies drawn from the 2013 IHGC GWA meta-analysis.**

Study	Cases		Controls	
	MA	MO	MA	MO
deCODE		537		34,617
ERF	141		1,216	
Finnish MA	1,032		3,513	
German MA	997		1,105	
German MO		1,208		2,564
HUNT		1,175		1,097
LUMINA MA	820		4,774	
LUMINA MO		1,118		2,016
NTR&NESDA	103		2,260	
TWINS UK	235		3,837	
WGHS	1,177		18,108	
Total	4,505	4,038	34,813	40,294

**Table S2. Biological functions significantly enriched for genes that overlap between MA and MO**

<b>Category</b>	<b>Disease or Function annotations</b>	<b>P-value</b>	<b># of Genes</b>	<b>Overlapping Genes</b>
Inflammatory Disease	Chronic inflammatory disorder	$4.1 \times 10^{-5}$	30	<i>AIF1, ARIH1, ART1, ATF6B, C4A/C4B, CHRNA10, CORT, CYP19A1, DHX16, EGFL8, G0S2, GABBR1, GABRA4, HDAC7, HPGD, HSD11B1, MICA, MSH5, PLA2G2A, PRRC2A, RNF39, SPP1, STAT6, STK19, TNXB, TRIM26, TRPM8, TSPO, UFL1, WNT5A</i>
Connective Tissue Disorders, Immunological Disease, Inflammatory Disease, Skeletal and Muscular Disorders	Rheumatoid arthritis	$4.7 \times 10^{-5}$	24	<i>AIF1, ARIH1, ART1, ATF6B, C4A/C4B, CYP19A1, DHX16, EGFL8, G0S2, GABRA4, HDAC7, MICA, MSH5, PLA2G2A, PRRC2A, RNF39, SPP1, STAT6, STK19, TNXB, TRIM26, TSPO, UFL1, WNT5A</i>
Organismal Injury and Abnormalities	Bleeding	$6.6 \times 10^{-5}$	17	<i>C1GALT1, C4A/C4B, CHRNA10, CYP19A1, ENG, FAIM, GABRA4, HDAC7, HEY2, JAG1, LRP1, NPHS2, PLA2G2A, SPP1, TIE1, VPS26A, ZFPM2</i>
Cardiovascular Disease, Developmental Disorder, Hereditary Disorder, Organismal Injury and Abnormalities	Tetralogy of Fallot	$1.0 \times 10^{-4}$	3	<i>HEY2, JAG1, ZFPM2</i>
Gastrointestinal Disease, Hepatic System Disease, Organismal Injury and Abnormalities	Congestion of liver	$1.2 \times 10^{-4}$	2	<i>ENG, HEY2</i>
Connective Tissue Disorders, Skeletal and Muscular Disorders	Arthropathy	$1.3 \times 10^{-4}$	29	<i>AIF1, ARIH1, ART1, ATF6B, C4A/C4B, CYP19A1, DHX16, EGFL8, G0S2, GABRA4, HDAC7, HPGD, LRP1, MICA, MMP16, MSH5, PLA2G2A, PRRC2A, RNF39, SCN9A, SPP1, STAT6, STK19, TIE1, TNXB, TRIM26, TSPO, UFL1, WNT5A</i>
Immunological Disease	Systemic autoimmune syndrome	$2.0 \times 10^{-4}$	30	<i>ABCF1, AIF1, ARIH1, ART1, ATF6B, C4A/C4B, C6orf48, CYP19A1, DHX16, EGFL8, G0S2, GABBR1, GABRA4, HDAC7, HSD11B1, IKZF3, MICA, MOG,</i>

				<i>MSH5, PLA2G2A, PRRC2A, RNF39, SPP1, STAT6, STK19, TNXB, TRIM26, TSPO, UFL1, WNT5A</i>
Connective Tissue Disorders, Inflammatory Disease, Skeletal and Muscular Disorders	Arthritis	$2.3 \times 10^{-4}$	28	<i>AIF1, ARIH1, ART1, ATF6B, C4A/C4B, CYP19A1, DHX16, EGFL8, G0S2, GABRA4, HDAC7, LRP1, MICA, MMP16, MSH5, PLA2G2A, PRRC2A, RNF39, SCN9A, SPP1, STAT6, STK19, TIE1, TNXB, TRIM26, TSPO, UFL1, WNT5A</i>
Cancer, Tumor Morphology	Mass of tumor	$2.6 \times 10^{-4}$	3	<i>ENG, JAG1, TGFA</i>
Cardiovascular Disease, Developmental Disorder	Patent ductus arteriosus	$3.4 \times 10^{-4}$	3	<i>HPGD, PLA2G2A, TFAP2B</i>
Endocrine System Disorders, Gastrointestinal Disease, Immunological Disease, Metabolic Disease	Insulin-dependent diabetes mellitus	$3.5 \times 10^{-4}$	16	<i>ABCF1, AIF1, C6orf48, DHX16, GABBR1, HSD11B1, IKZF3, MICA, MOG, MSH5, PRRC2A, RNF39, STAT6, STK19, TNXB, TRIM26</i>
Protein Synthesis	Quantity of prolactin (PRL) in blood	$5.3 \times 10^{-4}$	3	<i>CORT, CYP19A1, GABBR1</i>
Connective Tissue Disorders, Inflammatory Disease, Skeletal and Muscular Disorders	Rheumatic Disease	$6.3 \times 10^{-4}$	29	<i>AIF1, ARIH1, ART1, ATF6B, C4A/C4B, CYP19A1, DHX16, EGFL8, G0S2, GABRA4, HDAC7, LRP1, MICA, mir-10, MMP16, MSH5, PLA2G2A, PRRC2A, RNF39, SCN9A, SPP1, STAT6, STK19, TIE1, TNXB, TRIM26, TSPO, UFL1, WNT5A</i>
Cardiovascular System Development and Function, Cell Morphology, Embryonic Development	Branching morphogenesis of vasculature	$6.5 \times 10^{-4}$	3	<i>APH1A, C1GALT1, TIE1</i>
Cardiovascular Disease, Organismal Injury and Abnormalities	Atresia of tricuspid valve	$7.0 \times 10^{-4}$	2	<i>HEY2, ZFPM2</i>
Behavior	Avoidance	$7.0 \times 10^{-4}$	2	<i>OPN4, TRPM8</i>
Cancer, Gastrointestinal Disease	Primary gastric cancer	$7.0 \times 10^{-4}$	2	<i>SPP1, WNT5A</i>
Cancer	Breast or ovarian carcinoma	$7.2 \times 10^{-4}$	29	<i>ADAMTS8, APH1A, C4A/C4B, C6orf25, CTNNA1, CYP19A1, DTNA, FAM107B, FRYL, GART,</i>

				<i>GOLGB1, GPR20, HOXD3, HSD11B1, IFI27, mir-10, MS4A4A, NFATC4, OXCT2, PAFAH1B2, PSTPIP2, RALY, SPPI, SSC5D, TAGLN, TGFA, TMEM150B, TNXB, ZFPM2</i>
Neurological Disease	Absence seizure	$7.7 \times 10^{-4}$	4	<i>CA14, GABBR1, GABRA4, TSPO</i>
Neurological Disease	Epileptic encephalopathy	$7.7 \times 10^{-4}$	5	<i>CA14, GABBR1, GABRA4, SCN9A, TSPO</i>
Endocrine System Disorders, Gastrointestinal Disease, Metabolic Disease	Diabetes mellitus	$8.9 \times 10^{-4}$	28	<i>ABCF1, AIF1, ATP2A2, C6orf48, CA14, CYP19A1, DHX16, FXYD2, GABBR1, GABRA4, HPGD, HSD11B1, IKZF3, MICA, mir-10, MOG, MSH5, PRRC2A, PSMD11, RNF39, SCN9A, SLC30A8, SPPI, STAT6, STK19, TNXB, TRIM26, TSPO</i>

**Table S3. Canonical pathways significantly enriched for genes that overlap between MA and MO**

<b>Pathway</b>	<b>P-value</b>	<b>Overlapping Genes</b>
Notch Signaling	$7.8 \times 10^{-4}$	<i>MFNG, APH1A, HEY2, JAG1</i>
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate)	$3.2 \times 10^{-2}$	<i>PLA2G1B, TBXAS1, PLA2G2A</i>
L-carnitine Biosynthesis	$3.2 \times 10^{-2}$	<i>ALDH9A1</i>
GABA Receptor Signaling	$3.7 \times 10^{-2}$	<i>GABRA4, GABBR1, ALDH9A1</i>
5-aminoimidazole Ribonucleotide Biosynthesis I	$4.3 \times 10^{-2}$	<i>GART</i>
Geranylgeranyldiphosphate Biosynthesis	$4.3 \times 10^{-2}$	<i>FNTB</i>
MIF-mediated Glucocorticoid Regulation	$5.0 \times 10^{-2}$	<i>PLA2G1B, PLA2G2A</i>

**Table S4. Networks significantly enriched for genes that overlap between MA and MO**

<b>Top Diseases and Functions</b>	<b>P-value</b>	<b># of focus Genes</b>	<b>Genes<sup>a</sup></b>
Cardiovascular Disease, Organismal Injury and Abnormalities, Cardiac Stenosis	$1 \times 10^{-51}$	27	<i>Ap1, ATF7, ATP2A2, CEP70, Creb, CYP19A1, DLX3, FHL5, GABBR1, GABRA4, GIP, Gpcr, GPN3, GPR20, GPR139, GPR182, HEY2, Histone h3, Histone h4, HOXD3, MAF, MAP3K12, MICA, MSH5, NFkB(complex), PLA2G1B, PLA2G2A, RNA polymerase II, SP1, SPP1, STAT6, STAT5a/b, SUV39H2, TAGLN, USP8</i>
Hereditary Disorder, Neurological Disease, Connective Tissue Disorders	$1 \times 10^{-25}$	16	<i>ADCK3, AP4B1, AP4M1, AP4S1, BRSK1, C1GALT1, C1GALT1C1, CTNNAL1, FAIM, HSD17B7, HVCN1, IFT81, IFT88, MND1, NEK1, NOX5, POLE, POP4, POP7, PRSS1, RBBP9, RPP14, RPP21, RPP30, RPP38, RPP40, SERPINB8, SH2D3A, SLC29A1, STK10, STK19, STRADA, TEAD3, UBC, ZNF566</i>
Lipid Metabolism, Small Molecule Biochemistry, Molecular Transport	$1 \times 10^{-25}$	16	<i>ACSBG1, ACSL5, AIF1, APITD1/APITD1-CORT, ARIH1, ATF6B, BRMS1L, C1orf86, CREBZF, CUTC, FRYL, IDI1, IDI2, KIRREL, LCPI, LZTFL1, MBTPS2, MRPS21, NPHS2, PSTPIP2, RMI2, SARS2, SLC27A2, SLC27A3, SLC27A4, SLC27A6, SNTG1, STX2, STXBP3, SUV420H2, TTC8, TLL12, UBC, UFL1, USP44</i>
Cellular Movement, Connective Tissue Development and Function, Amino Acid Metabolism	$1 \times 10^{-25}$	16	<i>ALDH16A1, ALDH3B1, ALDH3B2, ALDH4A1, ALDH7A1, ALDH9A1, APBB1IP, ARPC3, ARPC1A, ARPC5L, CORO1B, DFFA, DHX16, DLGAP1, GMFB, GOLGB1, INPP5A, INPP5B, KIAA1671, NAP1L5, PARVG, RAB13, RAB11FIP4, RAB11FIP5, SLC19A1, SPI100, STRN3, SWAP70, TFAP2B, TRABD2B, TRIM26, UBC, WNT10B, WNT5A, WNT5B</i>
Cellular Assembly and Organization, Cancer, Endocrine System Disorders	$1 \times 10^{-24}$	16	<i>ACAN, ADAM20, ADAMTS8, ATP5C1, C6orf25, CA14, CCM2L, CDK5R1, CORT, CTAGE1, DLG4, DNAJAI, DNAJC22, DQX1, GPR89A/GPR89B, HSPA8, KLHDC8B, MARCH10, MITF, MPZL1, NME9, NPFF, PLEKHH3, PTPN11, SATB1, SSTR2, SUMO4, TGFA, TIE1, UBC, USP35, USP40, USP50, WFDC3, ZNF337</i>
Post-Translational Modification, Endocrine System Disorders, Hereditary Disorder	$1 \times 10^{-21}$	14	<i>AAAS, CFTR, CHD3, CHURC1-FNTB, CLCCI, CLOCK, ESYT1, ESYT2, ESYT3, FAM216A, GAN, ISG15, KDM1A, KIAA0922, NAE1, NAT14, NPHP4, PGR, PRKACA, RABAC1, RAD23A, RAD23B, RMDN2, RNF39, RPA3, SLC45A4, TBATA, TMEM194A, TRMT5, UBA3, UBC, UBE2F, UBE2M, UIMC1, ZNF260</i>

Hematological Disease, Molecular Transport, Cancer	$1 \times 10^{-21}$	14	<i>ANXA2R, BTAFL1, BTF3L4, CCNT2, DNAJB9, DNAJC14, DNAJC15, DUSP11, EAF2, ELAVL1, ELL3, FAM71C, FKBP9, GART, GLTSCR1L, KCTD9, LSM11, LSM14A, MTMR4, MTMR9, NELFA, PPTC7, PRR3, PTPLB, SLC11A2, SLC38A6, SLC48A1, SNRNP48, TBC1D5, TCEA2, VPS29, VPS26A, VPS26B, WDR47, ZCRB1</i>
Developmental Disorder, Organismal Injury and Abnormalities, Reproductive System Disease	$1 \times 10^{-21}$	14	<i>ALOX15B, AMHR2, AR, C12orf76, C4A/C4B, C5AR2, CCND1, CCRN4L, CDC40, DEPDC1, F2RL3, FFAR1, GPR125, GPR182, GPRC5A, INSM2, KCNMB1, KHDRBS1, KISS1R, MANBA, Muc1, NCOA1, p160, POU5F2, PPARG, PSMC3IP, PTPN21, RALY, SPATA13, SRC, SUZ12, TBXA2R, TBXAS1, TM7SF2, TRPM8</i>
Energy Production, Kidney Failure, Organismal Injury and Abnormalities	$1 \times 10^{-21}$	14	<i>ABCF1, ALKBH6, APH1A, ARL17A/ARL17B, ATP1A1, ATP1B1, CHD4, DTNA, FAM107B, FNTB, FUK, FUT6, FUT10, FXYD2, HDAC7, HHLA2, HNF1A, HNF4A, HSD11B1, IKZF2, IKZF3, INTS5, MRO, PAFAH2, POLR2A, PRR13, SLC26A1, SLC38A4, SLX4IP, SUMO2, TMEM140, UTP11L, ZBTB45, ZNF155, ZNF300</i>
Inflammatory Disease, Inflammatory Response, Respiratory Disease	$1 \times 10^{-20}$	14	<i>acetylcholine, ADAM8, ASTN2, CHRNA2, CHRNA4, CHRNA6, CHRNA9, CHRNA10, CHRN1, CHRN2, CHRN3, CHRND, CHRNE, CHRNG, EGFL8, ENG, IRF2BP2, ME1, MIR155HG, MS4A4A, MTMR11, PIGF, PRDM1, PRRC2A, PSMD11, RAD9B, RPS27, SIRT4, SSR3, ST14, TCTN1, TIMM8B, TP53, TSPO, ZFP36</i>
Cell Cycle, Cell Death and Survival, Cellular Assembly and Organization	$1 \times 10^{-20}$	14	<i>ANKRD13D, APBB2, APBB3, APP, CDCA2, CIART, DNAJC4, EGFR, FBLIM1, FILIP1, FXYD6, ganglioside GD1a, ganglioside GM2, ganglioside GT1, GLB1L, HPGD, HSF1, JAG1, LRPI, LYRM7, MMP16, MMP17, NUDT9, PHACTR4, PP2D1, PPPICC, PPP1R10, PPP1R32, PPP1R14B, PROM2, PRR16, RAB5C, RIN2, SH3BGRL3, SSH3</i>
Cellular Development, Skeletal and Muscular System Development and Function, Tissue Development	$1 \times 10^{-16}$	12	<i>ANKRD13A, ARHGAP20, ASCC1, CNTN1, ECM2, EDIL3, ELF1, FXN, G0S2, IFI27, LMOD1, mir-133, mir-143, mir-145, MYL4, MYLPF, MYOCD, NFATC4, NOM1, PAFAH1B2, PASK, PPP1CA, PPP1R18, PPP1R12C, PTPN7, SCN9A, SLC7A14, SMARCA4, SMOOTH MUSCLE ACTIN, SPOCD1, SRF, SRFBP1, TMOD3, Ubiquitin, ZNF628</i>
Cell Signaling, Molecular Transport, Vitamin and Mineral Metabolism	$1 \times 10^{-16}$	12	<i>ABLI, ADORA3, ADRBK1, BMP8B, BRINP1, CCR8, CELSR3, CHRD, COG3, DCLRE1C, EIF5A2, FPR1, FREM2, GIPR, GIT2, GPR45, GRPR, HDAC1, HRH1, HRH2, LTB4R, MDM2,</i>

			<i>NACC2, NPY1R, <b>OPN4</b>, OPRD1, PCBP2, <b>RRBP1</b>, Skor1, ST5, <b>STON2</b>, TACR1, <b>TARBP2</b>, TGIF2, <b>ZFPM2</b></i>
Hematological Disease, Hereditary Disorder, Organismal Injury and Abnormalities	$1 \times 10^{-16}$	12	<i>AGO2, <b>ANAPC7</b>, ARFGAP3, <b>ART1</b>, <b>C6orf48</b>, Cbp/p300-Hd-Taf4-Taf9b-Tbp, <b>DPF3</b>, EP300, HOXA10, <b>HOXD4</b>, HTT, Laminin, <b>MFNG</b>, mir-10, miR-100-5p (and other miRNAs w/seed ACCCGUA), miR-10a-5p (and other miRNAs w/seed ACCCUGU), <b>MOG</b>, NDUFA3, NFkB (family), p300-CBP, PARP, PARP3, PARP4, PARP6, PARP8, PARP11, PARP15, PARP16, <b>REG3A</b>, RELA, SEPP1, SSC5D, TIPARP, TNXB, <b>TRIP10</b></i>
<sup>a</sup> Focus genes (overlapping MA and MO) are shown in bold.			

<b>Table S5. Networks constructed by combining significant canonical pathways and biological functions</b>			
<b>Top Diseases and Functions</b>	<b>P-value</b>	<b>Focus Genes</b>	<b>Genes<sup>a</sup></b>
Carbohydrate Metabolism, Lipid Metabolism, Molecular Transport	$1 \times 10^{-32}$	14	<i>Acot1, ACOX2, <b>ATF6B</b>, BAAT, BMP5, ENG, <b>FAM107B</b>, FNTB, G0S2, HNF4A, HNF4A±dimer, HOXA10, <b>HSD11B1</b>, JAG1, LGALS1, LR1, MECR, MFNG, MMP14, MMP15, <b>MMP16</b>, MMP17, MMP26, MS4A4A, <b>PLA2G12B</b>, PLA2G1B, <b>PLA2G2A</b>, PLA2G2D, PRDM1, PZP, RXRA, sPla2, SSC5D, <b>TNXB</b>, <b>TRPM8</b></i>
Cellular Movement, Connective Tissue Development and Function, Amino Acid Metabolism	$1 \times 10^{-32}$	13	<i><b>ALDH16A1</b>, ALDH1B1, ALDH3B1, ALDH3B2, ALDH4A1, ALDH7A1, ALDH9A1, <b>ARIH1</b>, <b>DHX16</b>, GART, GOLGB1, <b>IFI27</b>, IFI44, MAGEL2, MAN2C1, MRPL13, MTPAP, NDUFA1, NFATC4, <b>PAFAH1B2</b>, <b>PRRC2A</b>, PSMD11, RALY, SLC19A1, <b>TBXAS1</b>, TFAP2B, TRABD2B, <b>TRIM26</b>, UBC, UBLCP1, <b>VPS26A</b>, VPS26B, WNT10B, WNT5A, WNT5B</i>
Connective Tissue Disorders, Neurological Disease, Organismal Injury and Abnormalities	$1 \times 10^{-25}$	14	<i>ADRBK1, AIFI, <b>CIGALT1</b>, <b>CIGALT1C1</b>, <b>C6orf25</b>, <b>CORT</b>, <b>CTNNAL1</b>, EMR2, FAIM, <b>FRYL</b>, GPR107, GPR108, GPR115, GPR126, GPR155, GPR176, GPR89A/GPR89B, HEATR6, MTMR8, <b>NPHS2</b>, NT5C, NUDT11, <b>OPN4</b>, PGAM4, PPAPDC2, <b>PPTC7</b>, <b>PSTPIP2</b>, PTPN11, <b>RNF39</b>, SSTR2, <b>STK19</b>, THTPA, TPTE, UBC, <b>UFL1</b></i>
Neurological Disease, Behavior, Immunological Disease	$1 \times 10^{-23}$	13	<i><b>ABCF1</b>, ACAN, ADAMTS8, APP, <b>CA14</b>, cholesterol, <b>EGFL8</b>, ETV4, <b>GABBRI</b>, <b>GABRA4</b>, Gpcr, <b>GPR20</b>, GPR62, GPR75, GPR97, GPR110, GPR111, GPR144, GPR152, GPR156, GPR157, GPR162, GPR171, GPR174, GPRC5D, GPRC6A, <b>HDAC7</b>, <b>HOXD4</b>, HPGD, HTT, <b>IKZF3</b>, MITF, <b>MOG</b>, <b>TIMM8B</b>, <b>TSPO</b></i>
Cardiovascular System Development and Function, Organ Morphology, Skeletal and Muscular System Development and Function	$1 \times 10^{-22}$	12	<i>ACP5, AHSP, <b>ATP2A2</b>, BTG3, CD69, <b>CYP19A1</b>, DUSP16, ESRRA, HAND1, <b>HEY2</b>, HIST1H3C, Histone h3, Histone h4, <b>HOXD3</b>, HPSE, <b>IDII</b>, IL9, KIR3DL1, LRWD1, MICA, <b>MSH5</b>, Mx1/Mx2, NFκB (complex), Pln, PSG5, REL/RELA/RELB, Scd2, SLN, <b>SPPI</b>, <b>STAT6</b>, TACC2, TAGLN, <b>TIE1</b>, TNFRSF4, <b>ZFPM2</b></i>
Molecular Transport, Organ Morphology, Skeletal and Muscular System Development and Function	$1 \times 10^{-7}$	5	<i>ANK3, <b>APHIA</b>, APH1B, ATP1A1, ATP1A2, ATP1A3, ATP1B1, ATP1B2, ATP1B3, D1Pas1, DTNA, DUSP2, EPCAM, FXYD1, <b>FXYD2</b>, FXYD7, KCNJ10, KCNJ12, MAGEE1, MAPK3, MAPK4, MLC1, MTMR2, Na-k-atpase, PTPN7, SCN1A, SCN4A, <b>SCN9A</b>, SLC15A1, SNTA1, SNTB1, SNTB2, <b>TGFA</b>, voltage-gated sodium channel, YME1L1</i>

<sup>a</sup> Focus genes (overlapping MA and MO) are shown in bold.